Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PM8002 + etoposide + platinum
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
PM8002 + etoposide + platinum is a combination regimen comprising PM8002, a bispecific monoclonal antibody that targets both programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor A (VEGF-A), etoposide, a topoisomerase II inhibitor, and a platinum-based chemotherapy agent (cisplatin or carboplatin). PM8002 blocks PD-L1 on tumor cells to restore T-cell function and neutralizes VEGF-A to inhibit angiogenesis, promoting both immune-mediated tumor killing and suppression of tumor vascularization. This regimen is under investigation for the treatment of extensive-stage small cell lung cancer (ES-SCLC) and has shown promising efficacy and disease control in frontline treatment of unresectable pleural and peritoneal mesothelioma. PM8002 was developed by Biotheus and is also referenced by the code BNT327 in certain clinical trials[1][2][3].
- Other names
- PM8002 + etoposide + platinumBNT327 + etoposide + platinum
02
Targets
TOP2A (DNA topoisomerase II)DNAVEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on PM8002 + etoposide + platinum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PM8002 + etoposide + platinum.